Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
Aim: To evaluate the cost utility and budget impact of second-line gefitinib for non-small cell lung cancer from a Thai payer perspective. Methods: A Markov model with three health states (pre-progression, post-progression and death) was constructed to estimate direct medical costs and outcomes comp...
محفوظ في:
المؤلفون الرئيسيون: | Thongprasert,S., Tinmanee,S., Permsuwan,U. |
---|---|
التنسيق: | مقال |
منشور في: |
Wiley-Blackwell
2015
|
الموضوعات: | |
الوصول للمادة أونلاين: | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84857528545&origin=inward http://cmuir.cmu.ac.th/handle/6653943832/38524 |
الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
المؤسسة: | Chiang Mai University |
مواد مشابهة
-
Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
بواسطة: Thongprasert S., وآخرون
منشور في: (2014) -
Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer
بواسطة: Thongprasert S., وآخرون
منشور في: (2014) -
Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
بواسطة: Thongprasert S., وآخرون
منشور في: (2017) -
Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
بواسطة: Sumitra Thongprasert, وآخرون
منشور في: (2018) -
Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
بواسطة: Sumitra Thongprasert, وآخرون
منشور في: (2018)